Association of adrenal metastases with outcomes in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab in the GETUG-AFU-26 NIVOREN phase II trial.

被引：0

作者：

Billon, Emilien

Dalban, Cecile

Oudard, Stephane

Chevreau, Christine

Laguerre, Brigitte

Barthelemy, Philippe

Borchiellini, Delphine

Geoffrois, Lionnel

Negrier, Sylvie

Joly, Florence

Thiery-Vuillemin, Antoine

Gross-Goupil, Marine

Rolland, Frederic

Priou, Frank

Mahammedi, Hakim

Tantot, Florence

Escudier, Bernard

Chabaud, Sylvie

Albiges, Laurence

Gravis, Gwenaelle

机构：

[1] Inst Paoli Calmettes, Marseille, France

[2] Ctr Leon Berard, Lyon, France

[3] Hop Europeen Georges Pompidou, Paris, France

[4] IUCT Oncopole Inst Claudius Regaud, Toulouse, France

[5] Ctr Eugene Marquis, Rennes, France

[6] Inst Cancerol Strasbourg Europe, Strasbourg, France

[7] Univ Cote dAzur, Ctr Antoine Lacassagne, Nice, France

[8] Ctr Alexis Vautrin, Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[9] Univ Lyon 1, Ctr Leon Berard, Dept Med Oncol, Lyon, France

[10] Ctr Francois Baclesse, Dept Med Oncol, Caen, France

[11] Univ Hosp Jean Minjoz, Besancon, France

[12] CHU Bordeaux, Hop St Andre, Bordeaux, France

[13] Inst Cancerol Ouest, Dept Med Oncol, St Herblain, France

[14] CHD Vendee Hop Oudairies, La Roche Sur Yon, France

[15] Ctr Jean Perrin, Clermont Ferrand, France

[16] UNICANCER, GETUG Grp, Paris, France

[17] Gustave Roussy, Villejuif, France

[18] Univ Paris Saclay, Gustave Roussy Canc Campus, Villejuif, France

[19] Aix Mareseille Univ, Inst Paoli Calmettes, Marseille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.348

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

348

引用

页数：3

共 50 条

[31] Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab
Lefort, Felix
Dalban, Cecile
Gross-Goupil, Marine
Laguerre, Brigitte
Chabaud, Sylvie
Escudier, Bernard
Albiges, Laurence
JAMA ONCOLOGY, 2023, 9 (09) : 1295 - 1298
[32] The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) plus ipilimumab (ipi).
Grewal, Kabir
Chauhan, Pankaj Kumar
Mukhida, Sagar S.
Tannir, Nizar M.
Venkatesh, Neha
Shah, Amishi Yogesh
Zurita, Amado J.
Johns, Andrew
Campbell, Matthew T.
Goswami, Sangeeta
Gao, Jianjun
Jonasch, Eric
Mcquade, Jennifer Leigh
Alhalabi, Omar
Msaouel, Pavlos
Hahn, Andrew Warren
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 545 - 545
[33] Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
Lee, Chung-Han
Voss, Martin H.
Carlo, Maria Isabel
Chen, Ying-Bei
Reznik, Eduard
Knezevic, Andrea
Lefkowitz, Robert A.
Shapnik, Natalie
Tassone, Diana
Dadoun, Chloe
Shah, Neil J.
Owens, Colette Ngozi
McHugh, Deaglan Joseph
Aggen, David Henry
Laccetti, Andrew Leonard
Kotecha, Ritesh
Feldman, Darren R.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
Ana M. Molina
Darren R. Feldman
Michelle S. Ginsberg
Glenn Kroog
Satish K. Tickoo
Xiaoyu Jia
Murielle Georges
Sujata Patil
Michael S. Baum
Victor E. Reuter
Robert J. Motzer
Investigational New Drugs, 2012, 30 : 335 - 340
[35] Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
Molina, Ana M.
Feldman, Darren R.
Ginsberg, Michelle S.
Kroog, Glenn
Tickoo, Satish K.
Jia, Xiaoyu
Georges, Murielle
Patil, Sujata
Baum, Michael S.
Reuter, Victor E.
Motzer, Robert J.
INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 335 - 340
[36] Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma
Chacon, Matias Rodrigo
Cutuli, Hernan J.
Bracarda, Sergio
Maruzzo, Marco
Bourlon, Maria Teresa
Jacobs, Carmel
Perez-Valderrama, Begona
Magri, Ignacio
Richardet, Martin
Centkowski, Piotr
Fu, Simon Yuen Fai
Gurman, Pablo
Konduri, Srivani
Yu, Zhuoxin
Vezina, Heather
George, Saby
Albiges, Laurence
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[37] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, Robert J.
Rini, Brian I.
McDermott, David F.
Redman, Bruce G.
Kuzel, Timothy M.
Harrison, Michael R.
Vaishampayan, Ulka N.
Drabkin, Harry A.
George, Saby
Logan, Theodore F.
Margolin, Kim A.
Plimack, Elizabeth R.
Lambert, Alexandre M.
Waxman, Ian M.
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1430 - 1437
[38] ASSESSMENT OF SURGICAL COMPLICATIONS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC) RECEIVING PERIOPERATIVE CABOZANTINIB AND NIVOLUMAB ON CYTO-KIK CLINICAL TRIAL
Runcie, Karie
Ornstein, Moshe
Saraiya, Biren
Krishnamurthi, Venkatesh
Lee, Byron
Anderson, Christopher
DeCastro, Guarionex
McKiernan, James
Mayer, Tina
Dallos, Matthew
Stein, Mark
Singer, Eric
JOURNAL OF UROLOGY, 2023, 209 : E724 - E724
[39] Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.
Motzer, Robert J.
Rini, Brian I.
McDermott, David F.
Redman, Bruce G.
Kuzel, Timothy
Harrison, Michael Roger
Vaishampayan, Ulka N.
Drabkin, Harry A.
George, Saby
Logan, Theodore F.
Margolin, Kim Allyson
Plimack, Elizabeth R.
Waxman, Ian
Lambert, Alexandre
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
Conduit, Ciara
Davis, Ian D.
Goh, Jeffrey C.
Kichenadasse, Ganessan
Gurney, Howard
Harris, Carole A.
Pook, David
Krieger, Laurence
Parnis, Francis
Underhill, Craig
Adams, Diana
Roncolato, Felicia
Joshua, Anthony
Ferguson, Tom
Prithviraj, Prashanth
Morris, Michelle
Harrison, Michelle
Begbie, Stephen
Hovey, Elizabeth
George, Mathew
Liow, Elizabeth C.
Link, Emma K.
McJannett, Margaret
Gedye, Craig
BJU INTERNATIONAL, 2024, 133 : 57 - 67

← 1 2 3 4 5 →